Skip to main content
VCbacked
Log inGet Started

uFraction8

Falkirk, United Kingdom

uFraction8 develops microfluidics-based filtration systems to help bio-manufacturers to harvest biomass sustainably and more efficiently.

$4.3M raised
Feb 2025
Venture - Series Unknown
BiotechnologyCleanTechIndustrial EngineeringManufacturing

Top Investors

Foresight GroupScottish EnterpriseBlue Horizon CorporationCreative Destruction Lab (CDL)EIT Food

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about uFraction8

How much funding has uFraction8 raised?
uFraction8 has raised $4.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2025.
Who are uFraction8's investors?
uFraction8's investors include Foresight Group, Scottish Enterprise, Blue Horizon Corporation, Creative Destruction Lab (CDL), EIT Food.
Where is uFraction8 headquartered?
uFraction8 is headquartered in Falkirk, United Kingdom.
What does uFraction8 do?
uFraction8 develops microfluidics-based filtration systems to help bio-manufacturers to harvest biomass sustainably and more efficiently.
What stage is uFraction8 at?
uFraction8 is at the Venture - Series Unknown stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"uFraction8 — Funding & Investors." VCBacked, February 24, 2025, https://www.vcbacked.co/company/ufraction8. Accessed June 3, 2026.
APA
VCBacked. (2025). uFraction8 — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/ufraction8
Wikipedia (cite web)
{{cite web |title=uFraction8 — Funding & Investors |url=https://www.vcbacked.co/company/ufraction8 |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong